News
News from us and our partners
News
News
Biovelocita
News
Crossover
News
News
Industrial Biotech
News
Capital
News
Digital Medicine
News
Sofinnova Partners raises €1.2 billion to fuel the next wave of life sciences innovation
Sofinnova Partners exceeds target with €165M biotech acceleration fund, Europe’s largest, with strong Pharma support
CEO spotlight: Thierry Abribat's third straight win
Sofinnova’s newest partners discuss their career paths
Sofinnova publishes 2023 Impact Report
Johnson & Johnson to acquire Shockwave Medical
Cure51 raises €15 million to harness the power of cancer survivors
CEO spotlight: CinCor's Marc de Garidel
Tags
Topics
0 results
- News
Galvanize Therapeutics raises $100 million in oversubscribed Series C financing to transform the treatment of cancer and chronic lung disease
- News
BrightHeart Sets New Standard in Prenatal CHD Screening with Landmark Study Published in Obstetrics & Gynecology
- News
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial
- News
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
- News
Artios Pharma Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib (ART0380) into Late-stage Development
- News
NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor
- News
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
- News
Bioptimus Strengthens Commercial and Scientific Leadership with Key Hires
- News
Pi-Cardia’s ShortCut™ becomes First Leaflet Modification Technology to receive CMS NTAP for Valve-in-Valve TAVR
- News
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
- News
Nuage Therapeutics welcomes Olivier Corminboeuf and Blandine Guimet to Leadership Team
- News
Abivax Announces Closing of $747.5 Million Public Offering
- News
TISSIUM announces U.S. commercial launch of COAPTIUM® Connect and strategic governance evolution
- News
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
- News
Introducing Latent-X, a frontier generative AI model for protein binder design accessible via no-code platform for push-button protein design